Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of suvratoxumab to prevent nosocomial pneumonia in mechanically ventilated ICU patients colonized with Staphylococcus aureus
NL-OMON51453Phase 3Not yet recruiting
- Sponsor
- Aridis Pharmaceuticals, Inc.
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hospital-acquired pneumonia (HAP) and staphylococcal pneumonia comparing Suvratoxumab with Placebo (2 arms). Primary endpoint: Incidence of nosocomial all-cause pneumonia. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
Suvratoxumab
03
Conditions
hospital-acquired pneumonia (HAP)staphylococcal pneumonia
Beyond the preview
Go deeper on NL-OMON51453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51453.